AFP 464

Drug Profile

AFP 464

Alternative Names: AFP-464; NSC 710464

Latest Information Update: 30 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Kirax Corporation
  • Class Antineoplastics; Flavonoids
  • Mechanism of Action Apoptosis stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Solid tumours

Most Recent Events

  • 01 Jul 2013 The National Cancer Institute completes a phase I trial in Solid tumours (late stage disease, second-line therapy or greater) in USA (NCT00348699)
  • 09 Aug 2012 Tigris Pharmaceuticals is now called Kirax Corporation
  • 06 Jan 2012 Kirax terminates phase II trial in Breast cancer in USA (NCT01233947)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top